Dr. Tapas Kumar Koley Author of Evaluating Organization Development
FEATURED AUTHOR

Dr. Tapas Kumar Koley

Senior Specialist Physician
South Delhi Municipal Corporation

I received the degree of M. D (Internal Medicine) from PGIMS Rohtak, Haryana, India in the year 1996. I joined the department of Internal Medicine at Hindu Rao Hospital, under North Delhi Municipal Corporation, in the same year as Medical Officer. From 2004 onwards I am working as Senior Specialist Physician at Tilak Nagar Colony Hospital, under South Delhi Municipal Corporation.

Biography

I am born and brought up in New Delhi, which is the vibrant capital of India. I have done my schooling in Union Academy Senior Secondary School which is situated at central Delhi. During my schooling I developed a deep interest in Biological Science and decided to study Medicine.

Areas of Research / Professional Expertise

    I am deeply involved in patient care in the department of Medicine at Tilak Nagar Colony Hospital. However, I am interested in writing on various topics of medicine in a simplified manner. My main work is on Covid-19, the raging global pandemic. Besides this, I have also written on medical negligence which is a part of medical law and electrocardiography. I am involved in training of doctors and lawyers in the field of medical negligence.

Personal Interests

    Music, Photography, Reading

Books

Featured Title
 Featured Title - COVID-19 Pandemic -- Koley and Dhole - 1st Edition book cover

News

Eli Lilly Monoclonal Antibody Treatment for Covid-19

By: Dr. Tapas Kumar Koley

Eli Lilly's Monoclonal Antibody Bamlanivimab Treatment for Covid-19

According to Reuters, the Food and Drug Administration (FDA) granted emergency use authorization (EUA) to Eli Lilly & Co's LLY.N bamlanivimab, a monoclonal antibody for the treatment of mild to moderate cases of Covid-19 as it was found to reduce the need for hospitalization or emergency room visits in high-risk COVID-19 patients.

It is not authorized for treatment of severe or hospitalized patients of Covid-19.

The company hopes to manufacture up to one million doses of the medicine by the year end, for use around the world through early next year. 

WHO: Global Update on Covid-19, November 11, 2020

By: Dr. Tapas Kumar Koley

WHO: Global Update on Covid-19

According to WHO, the total number of Covid-19 cases as reported on November 11, 2020 is 50,810,763 and total deaths is 1,263,844. The region of the Americas and Europe are badly affected. In India the number of cases have started declining recently.

The top three worst affected countries are USA (9,868,389 cases), India (8,636,011 cases) and Brazil (5675,032).

The top three worst affected countries in terms of Covid deaths are USA (236,042), Brazil (162,628) and India (127,571). In last 24 hours USA reported 1192 deaths, France reported 546 deaths and India reported 512 deaths.

Pfizer and BioNTech Covid-19 Vaccine

By: Dr. Tapas Kumar Koley

Pfizer and BioNTech Covid-19 Vaccine

BBC has reported that according to a preliminary analysis, the first effective coronavirus vaccine developed by Pfizer and BioNTech can prevent more than 90% of people from getting Covid-19. The vaccine has been tested on more than 40,000 people across six countries without any severe side effect. The companies plan to apply for authorization of its use by the end of November.

Two doses are given three weeks apart and more than 90% proection is achieved after seven days of second injection. The two companies have reported that they will be able to supply 50 million doses by the end of this year and around 1.3 billion by the end of 2021.

However, the main problem is that the vaccine requires storage below minus 80 degree celsius.